Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature
Launched by BOSTON SCIENTIFIC CORPORATION · Dec 14, 2020
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
The ELEGANCE Registry is a clinical trial that aims to gather important information about the real-world use of drug-eluting devices made by Boston Scientific for treating peripheral vascular diseases (PVD). These are conditions that affect blood vessels outside of the heart and brain. The study is designed to include a diverse group of patients, especially those who may not have been represented in earlier trials. By collecting data from everyday clinical settings, the trial hopes to ensure the safe and effective use of these devices.
To be eligible for this study, patients must be 18 years or older and provide consent to allow their information to be used. Participants will have received a specific Boston Scientific drug-eluting device for their treatment. However, those who are not expected to live for at least a year are not eligible to join. If you choose to participate, you will help researchers understand how these devices perform in real-life situations, which could lead to better treatment options for everyone with similar conditions.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients 18 years and older
- • Written informed consent (patient data release-form)
- • Use of any commercially available Boston Scientific drug-eluting device marketed for treatment of lesions in the peripheral vasculature and specified in the Registry Enrollment Guide
- Exclusion Criteria:
- • Life expectancy of \<1 year
About Boston Scientific Corporation
Boston Scientific Corporation is a global leader in medical device innovation, dedicated to providing solutions that enhance patient care and improve clinical outcomes. With a strong focus on advancing the treatment of various medical conditions, Boston Scientific develops and manufactures a diverse range of products across multiple specialties, including cardiology, urology, and endoscopy. The company is committed to rigorous clinical research and development, ensuring that its devices meet the highest standards of safety and efficacy. Through collaboration with healthcare professionals and ongoing investment in technology and education, Boston Scientific strives to deliver breakthrough therapies that address unmet medical needs and empower patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Houston, Texas, United States
Durham, North Carolina, United States
Cleveland, Ohio, United States
Charleston, South Carolina, United States
Cleveland, Ohio, United States
New York, New York, United States
Boston, Massachusetts, United States
Newark, New Jersey, United States
Hackensack, New Jersey, United States
Perth, Western Australia, Australia
Tallahassee, Florida, United States
Washington, District Of Columbia, United States
Cleveland, Ohio, United States
New Haven, Connecticut, United States
Providence, Rhode Island, United States
Houma, Louisiana, United States
Philadelphia, Pennsylvania, United States
Chicago, Illinois, United States
Lubbock, Texas, United States
Austin, Texas, United States
Lafayette, Louisiana, United States
Sabadell, , Spain
Los Angeles, California, United States
Valdosta, Georgia, United States
Chongqing, Chongqing, China
Philadelphia, Pennsylvania, United States
Los Angeles, California, United States
Fairfax, Virginia, United States
Browns Mills, New Jersey, United States
Los Angeles, California, United States
Jonesboro, Arkansas, United States
New York, New York, United States
Taipei City, , Taiwan
Graz, , Austria
St. Leonards, , Australia
Atlanta, Georgia, United States
Houma, Louisiana, United States
Hangzhou, Zhejiang, China
New York, New York, United States
Sacramento, California, United States
Hat Yai, , Thailand
Rapid City, South Dakota, United States
Chaoyang, Beijing, China
Los Angeles, California, United States
Seattle, Washington, United States
Sherbrooke, Quebec, Canada
Indianapolis, Indiana, United States
Harrisburg, Pennsylvania, United States
Tulsa, Oklahoma, United States
München, , Germany
Taiyuan, Shanxi, China
Saint Helena, California, United States
Newport, Delaware, United States
Boynton Beach, Florida, United States
Springfield, Illinois, United States
Fort Wayne, Indiana, United States
Kenner, Louisiana, United States
Coon Rapids, Minnesota, United States
Tupelo, Mississippi, United States
Newark, New Jersey, United States
Buffalo, New York, United States
Manhasset, New York, United States
Raleigh, North Carolina, United States
Dayton, Ohio, United States
Austin, Texas, United States
Plano, Texas, United States
Chaoyang, Beijing, China
Xicheng, Beijing, China
Guangzhou, Guangdong, China
Qingdao, Shandong, China
Huangpu, Shanghai, China
Yangpu, Shanghai, China
Xi'an, Shanxi, China
Shanghai, Xuhui District, China
Taichung, , Taiwan
Bangkok, , Thailand
Calgary, Alberta, Canada
Paris, , France
Essen, , Germany
New York, New York, United States
Le Plessis Robinson, , France
Bruchsal, , Germany
New York, New York, United States
Poznań, , Poland
Dallas, Texas, United States
Kenner, Louisiana, United States
Plano, Texas, United States
Sherbrooke, Quebec, Canada
Sabadell, , Spain
Brown Mills, New Jersey, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials